Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830)
- 1 November 1989
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 12 (6) , 495-510
- https://doi.org/10.1016/0732-8893(89)90084-9
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobesAntimicrobial Agents and Chemotherapy, 1986
- Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in miceJournal of Antimicrobial Chemotherapy, 1986
- Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamasesAntimicrobial Agents and Chemotherapy, 1986
- In vitro activity and disk susceptibility of timentin: current statusThe American Journal of Medicine, 1985
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limitsAntimicrobial Agents and Chemotherapy, 1983
- Pharmacokinetics of sulbactam in humansAntimicrobial Agents and Chemotherapy, 1983
- β-Lactamase inhibitors in perspectiveJournal of Antimicrobial Chemotherapy, 1983
- Piperacillin susceptibility tests by the single-disk agar diffusion techniqueAntimicrobial Agents and Chemotherapy, 1979
- CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological CharacterizationAntimicrobial Agents and Chemotherapy, 1978